AOLS Recent News Aeolus Announces First Quarter F
Post# of 14
Posted On: 03/02/2014 1:58:19 PM
AOLS Recent News
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results Marketwire - Fri Feb 14, 4:30PM CST
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation Marketwire - Thu Feb 13, 6:30AM CST
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies Marketwire - Mon Feb 10, 6:30AM CST
Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure M2 - Fri Jan 24, 5:42AM CST
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA Marketwire - Thu Jan 23, 9:53AM CST
Aeolus Announces Fiscal Year 2013 Financial Results Marketwire - Mon Dec 23, 7:00AM CST
Aeolus Pharmaceuticals Inc submits application for new patent for AEOL 10150 for use in radiation exposure M2 - Fri Dec 06, 9:50AM CST
Aeolus Files Application for New Patent on AEOL 10150 Marketwire - Thu Dec 05, 10:15AM CST
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation Marketwire - Tue Oct 29, 7:01AM CDT
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome Marketwire - Tue Sep 17, 12:30PM CDT
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results Marketwire - Fri Feb 14, 4:30PM CST
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation Marketwire - Thu Feb 13, 6:30AM CST
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies Marketwire - Mon Feb 10, 6:30AM CST
Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL 10150 to treat patients exposed to acute radiation exposure M2 - Fri Jan 24, 5:42AM CST
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA Marketwire - Thu Jan 23, 9:53AM CST
Aeolus Announces Fiscal Year 2013 Financial Results Marketwire - Mon Dec 23, 7:00AM CST
Aeolus Pharmaceuticals Inc submits application for new patent for AEOL 10150 for use in radiation exposure M2 - Fri Dec 06, 9:50AM CST
Aeolus Files Application for New Patent on AEOL 10150 Marketwire - Thu Dec 05, 10:15AM CST
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation Marketwire - Tue Oct 29, 7:01AM CDT
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome Marketwire - Tue Sep 17, 12:30PM CDT
(0)
(0)